What is the address of IMMOMAB?

The registered office of IMMOMAB is located at Rue Jules Destrée(WAN) 134, 6220 Fleurus.

Is IMMOMAB still active?

Yes. According to the CBE (30 October 2026) IMMOMAB is active, legal situation “Normale toestand”, started on 15 December 1999.

Is IMMOMAB registered on Peppol?

No, IMMOMAB is currently not registered on the Peppol network.

What is the enterprise number of IMMOMAB?

The enterprise number of IMMOMAB is BE0468300657.

When was IMMOMAB founded?

IMMOMAB was founded on 15 December 1999.

Who are the directors of IMMOMAB?

According to the 2025 annual accounts, the directors of IMMOMAB are: Jean-Pol MABILLE, Catherine GIGOT.

Is IMMOMAB a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 15 December 1999; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did IMMOMAB make in 2025?

IMMOMAB posted a profit after taxes of € 4,848 in financial year 2025.

What is the revenue of IMMOMAB?

As a small company, IMMOMAB is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 8,893.

IMMOMAB (Public Limited) - Fleurus - BE0468300657

Dossier IMMOMAB, printed on 30 October 2026 from databakkes.be/en/0468300657/immomab. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

IMMOMAB from Fleurus, company number BE0468300657, closed financial year 2025 with a result of € 4,848 after tax. For that financial year IMMOMAB recorded a gross margin of € 8,893 and equity of € 49,036. Compared with financial year 2024, the result moved from € 4,486 to € 4,848. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 24, 2026.

What it is worth Growing

€ 49,036

▲ 11% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 4,848

▲ 8% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 8,250

▼ 40% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € -32,768.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 709

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 7,681 Gross margin 2022: € 7,681 First fiscal year in the series	€ 7,222 Gross margin 2023: € 7,222 ▼ 6% vs 2022 (€ 7,681) Unfavourable step	€ 8,737 Gross margin 2024: € 8,737 ▲ 21% vs 2023 (€ 7,222) Favourable step	€ 8,893 Gross margin 2025: € 8,893 ▲ 2% vs 2024 (€ 8,737) Favourable step	▲ 2%
Profit after taxes	€ 2,657 Profit after taxes 2022: € 2,657 First fiscal year in the series	€ 2,899 Profit after taxes 2023: € 2,899 ▲ 9% vs 2022 (€ 2,657) Favourable step	€ 4,486 Profit after taxes 2024: € 4,486 ▲ 55% vs 2023 (€ 2,899) Favourable step	€ 4,848 Profit after taxes 2025: € 4,848 ▲ 8% vs 2024 (€ 4,486) Favourable step	▲ 8%
Equity	€ 36,803 Equity 2022: € 36,803 First fiscal year in the series	€ 39,702 Equity 2023: € 39,702 ▲ 8% vs 2022 (€ 36,803) Favourable step	€ 44,189 Equity 2024: € 44,189 ▲ 11% vs 2023 (€ 39,702) Favourable step	€ 49,036 Equity 2025: € 49,036 ▲ 11% vs 2024 (€ 44,189) Favourable step	▲ 11%
Total debts	€ 0 Total debts 2022: € 0 First fiscal year in the series	€ 0 Total debts 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Total debts 2024: € 0 Unchanged (€ 0) Unchanged	€ 709 Total debts 2025: € 709 Unchanged (€ 0) Unfavourable step
Cash	€ 15,499 Cash 2022: € 15,499 First fiscal year in the series	€ 8,885 Cash 2023: € 8,885 ▼ 43% vs 2022 (€ 15,499) Unfavourable step	€ 13,643 Cash 2024: € 13,643 ▲ 54% vs 2023 (€ 8,885) Favourable step	€ 8,250 Cash 2025: € 8,250 ▼ 40% vs 2024 (€ 13,643) Unfavourable step	▼ 40%
Retained profit	€ -45,002 Retained profit 2022: € -45,002 First fiscal year in the series	€ -42,103 Retained profit 2023: € -42,103 ▲ € 2,899 vs 2022 (€ -45,002) Favourable step	€ -37,616 Retained profit 2024: € -37,616 ▲ € 4,486 vs 2023 (€ -42,103) Favourable step	€ -32,768 Retained profit 2025: € -32,768 ▲ € 4,848 vs 2024 (€ -37,616) Favourable step	▲ € 4,848
Balance sheet total	€ 36,803 Balance sheet total 2022: € 36,803 First fiscal year in the series	€ 39,702 Balance sheet total 2023: € 39,702 ▲ 8% vs 2022 (€ 36,803) Unchanged	€ 44,189 Balance sheet total 2024: € 44,189 ▲ 11% vs 2023 (€ 39,702) Unchanged	€ 49,746 Balance sheet total 2025: € 49,746 ▲ 13% vs 2024 (€ 44,189) Unchanged	▲ 13%

Key figures of IMMOMAB, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to IMMOMAB?

What happened at IMMOMAB in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 24, 2026 New annual accounts for financial year 2025: profit of € 4,848 (▲ 8% vs 2024). Source: NBB ↗
1999 Jean-Pol MABILLE became a director. NBB
Dec 15, 1999 Start of the company according to the CBE. KBO

In short

From € 2,657 profit in 2022 to € 4,848 profit in 2025.

Best year ever: 2025, with € 4,848 profit.

Original PDFs at the National Bank ↗

Management

Jean-Pol MABILLE Catherine GIGOT

MABILLE CABINET MEDICAL

IMMOMAB

Behind IMMOMAB are Jean-Pol MABILLE and Catherine GIGOT. Jean-Pol MABILLE is also behind MABILLE CABINET MEDICAL.

Directors

According to the 2025 annual accounts

Jean-Pol MABILLE

Director

Also active at: MABILLE CABINET MEDICAL

since 1999

Catherine GIGOT

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Jules Destrée(WAN) 134

6220 Fleurus

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

MABILLE CABINET MEDICAL same network

€ 97,610 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0468.300.657
VAT number: BE 0468.300.657
Registered office: Rue Jules Destrée(WAN) 134, 6220 Fleurus
Names & denominations: IMMOMAB
Enterprise type: Rechtspersoon
Legal form: Public limited company
Legal situation: Normale toestand
Start date: 15 December 1999
Peppol: Not registered

View on CBE Public ↗ Annual accounts (NBB) ↗